Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for Sept. 16-17, 2026, in Jersey City, New Jersey. The forum provides a platform for experts in nasal drug development to discuss innovations and challenges in the field.
CEO Eric Weisblum emphasized the significance of the event, stating that it offers an opportunity to engage with key opinion leaders as Silo continues to advance SPC-15, its novel nose-to-brain approach for targeted drug delivery in the treatment of post-traumatic stress disorder (PTSD). The company has reported preclinical data demonstrating that the SPC-15 formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality through nine months. Additionally, six-month accelerated stability data were consistent and aligned with long-term stability findings, indicating the product's robustness.
The participation in this forum is crucial for Silo Pharma as it seeks to validate its drug delivery platform and potentially accelerate the development timeline for SPC-15. PTSD is a significant unmet medical need, affecting millions worldwide, and current treatment options are often limited or ineffective. Silo's innovative approach could offer a new therapeutic avenue, and the stability data provides confidence in the product's viability.
The company's therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories, enhancing its scientific credibility.
By participating in the IPAC-RS forum, Silo Pharma aims to network with potential partners and stay abreast of regulatory and technical advancements in nasal drug delivery. This engagement is part of a broader strategy to bring innovative treatments to market and address underserved patient populations. For more information about Silo Pharma, visit silopharma.com.
The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
